Systemic inflammation in a melanoma patient treated with immune checkpoint inhibitors—an autopsy study

BACKGROUND: Immune checkpoint inhibitors targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and programmed cell death protein 1 (PD-1) have been recently approved for treatment of patients with metastatic melanoma and non-small cell lung cancer (NSCLC). Despite important clinical benefit...

Descripción completa

Detalles Bibliográficos
Autores principales: Koelzer, Viktor H., Rothschild, Sacha I., Zihler, Deborah, Wicki, Andreas, Willi, Berenika, Willi, Niels, Voegeli, Michèle, Cathomas, Gieri, Zippelius, Alfred, Mertz, Kirsten D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791920/
https://www.ncbi.nlm.nih.gov/pubmed/26981243
http://dx.doi.org/10.1186/s40425-016-0117-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4791920/
https://www.ncbi.nlm.nih.gov/pubmed/26981243
http://dx.doi.org/10.1186/s40425-016-0117-1

Ejemplares similares